|
 |
Anti-TNFThis page contains recent news articles, when available, and an overview of Anti-TNF but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.In line with recommendations from the American College of Rheumatology, physicians surveyed by MedPage Today and ABC News unanimously agreed that anti-TNF ... MedPage Today Ocrelizumab Hits Endpoint in RA Trial; Safety Questions Remain - Dec 11, 2009 Rituxan (rituximab) from Genentech and Biogen already has approval for rheumatoid arthritis patients who have failed anti-TNF-alpha therapy. ... BioWorld Online New and Upcoming Biologic Agents for Rheumatoid Arthritis - Dec 29, 2009 On April 24, 2009 the Food and Drug Administration (FDA) approved golimumab (Simponi, Centocor), an anti-TNF-æ±? monoclonal antibody, with an indication for ... Ortho SuperSite Active immunization to tumor necrosis factor-alpha is effective in treating ... - Dec 23, 2009 Conclusions: Anti-TNF-alpha immunotherapy with TNF-K has a sustained, but reversible therapeutic efficacy in an established disease model, supporting the ... 7thSpace Interactive (press release) MP Andrew George exercises to keep condition at bay - Dec 14, 2009 Andrew takes basic anti-inflammatories, but says he has campaigned vigorously to get the expensive anti-TNF (tumour necrosis factor) drugs available to all. ... BBC News TNF Blockers: Miracle Drugs or Minefields? - Dec 17, 2009 The anti-TNF monoclonal antibodies are intended to simply block TNF from attaching to its receptors. A second approach is to tie up TNF with receptors that ... EmpowHer (blog) UCB reveals results of trial into safety of certolizumab pegol - Dec 21, 2009 The humanised anti-TNF alpha monoclonal antibody brought about remission of the condition in 32 per cent of patients after a period of six weeks, ... Zenopa Centocor's $1.67B Court Win Versus Abbott Upheld - Dec 18, 2009 ...been engaged in patent disputes over the competing therapies and a newer product, which belong to a class called antitumor necrosis factor, or anti-TNF. ... Wall Street Journal Cimzia Draws Even With Simponi at Six Months Post Launch According to Recent ... - Dec 23, 2009 Among Rheumatologists who have used the new anti-TNF products, overall satisfaction has increased to 60% with Simponi and 50% with Cimzia. ... PR Newswire (press release) Study results show associated improvements under treatment with Cimzia - Dec 9, 2009 UCB today announced new published data showing that Cimzia, the only approved PEGylated anti-TNF, plus methotrexate (MTX), rapidly improved home and ... Pharmacy Europe NICE seeks more data from Roche for RoActemra appraisal - Dec 17, 2009 Stressing that there is a “clear unmet need for people who fail on Anti-TNF therapyâ€?, its chief executive Ailsa Bosworth said the decision is “a bitter blow ... Pharma Times ABLYNX DEMONSTRATES PROOF-OF-CONCEPT BY BIOMARKER FOR ITS ANTI-THROMBOTIC ALX-0081 - Dec 23, 2009 In addition, in December 2008, Ablynx's partner Pfizer entered a Phase I study with an anti- TNF-alpha Nanobody and a Phase II study was initiated in ... PipelineReview.com (press release) 2009 Big Pharma DOTY Nominee: Merck/Schering-Plough - Dec 16, 2009 Per the companies' 1998 agreement granting Schering ex-US rights to anti-TNF drugs Remicade (and follow-on Simponi), J&J has a change of control clause ... The IN VIVO Blog (blog) ABLYNX INITIATES PHASE I FOR ALX-0141 (ANTI-RANKL) - Dec 16, 2009 There are now four Nanobodies in clinical trials including Pfizer's anti-TNF-alpha Nanobody which entered Phase II in September 2009 in patients with ... PipelineReview.com (press release) Neovacs Initiates a Phase II Clinical Trial of TNFa Kinoid in Rheumatoid Arthritis - Dec 9, 2009 ...“Anti-TNF monoclonals are very effective, but often lose their efficacy over time. ADAs are a major factor in this therapeutic failureâ€?, commented Professor ... ADMET.net Cost-utility analysis of infliximab and adalimumab for refractory ulcerative ... - Dec 12, 2009 Conclusions: The ICURs of anti-TNF-alpha drugs were not satisfactory in treating patients with moderate-to-severe refractory UC. Future research could be ... 7thSpace Interactive (press release) Ablynx Initiates Phase I For ALX-0141 (ANTI-RANKL) - Dec 17, 2009 There are now four Nanobodies in clinical trials including Pfizer's anti-TNF-alpha Nanobody which entered Phase II in September 2009 in patients with ... BioResearch Online (press release) Se celebran las 3as Jornadas BEI (Biomedicina y Enfermedades Inflamatorias ... - Dec 16, 2009 ...“Certolizumab pegol aporta como principal novedad el diseño particular de su molécula, diferente al resto de anti-TNF. Se trata del primer antagonista del ... Árbol de Noticias Biologiska läkemedel ger bestÃ¥ende högre livskvalitet - Dec 18, 2009 Hans avhandling Measure for Measure beskriver den hälsorelaterade livskvaliteten vid sÃ¥ kallad anti-TNF-behandling för knappt 2 500 patienter som har ... MyNewsdesk (pressmeddelande) Edwin Moses (Ablynx): “We brengen al het vierde Nanobody naar klinische studie ... - Dec 14, 2009 Er zijn momenteel vier Nanobodies in klinische studies, waaronder Pfizer's anti-TNF-alfa Nanobody dat in september 2009 Fase II startte in patiënten met ... Cash.be UCB maakt eerste klinische testresultaten bekend van patiënten die ... - Dec 20, 2009 Over certolizumab pegol Certolizumab pegol is de enige gepegyleerde anti-TNF (tumornecrosefactor). Het heeft een hoge affiniteit voor menselijk TNF-alfa en ... Analist.be (persbericht) «Οι Ï?ευματικÎÏ‚ παθήσεις μποÏ?εί να Îχουν σαÏ?ωτικÎÏ‚ επιδÏ?άσεις» - Dec 19, 2009 Οι θεÏ?απείες αυτÎÏ‚, όπως για παÏ?άδειγμα τα φάÏ?μακα/αντίδοτα στη δÏ?άση του παÏ?άγοντα νÎκÏ?ωσης όγκων (anti-TNF), αλλά και διάφοÏ?α άλλα που αÏ?χίζουν να είναι ... Η Έρευνα Les nouveaux résultats de l'étude montrent que les patients vivent plus ... - Dec 9, 2009 ...ayant montré une réponse inadéquate ou une intolérance à un ou plusieurs traitements par des inhibiteurs du facteur de nécrose tumorale (anti-TNF)(2). ... CNW Telbec (Communiqué de presse) Anti-tumor Necrosis Factor Treatment Does Not Increase Cancer Risk In ... - Oct 29, 2009 Researchers identified and analyzed data from 6366 patients who started anti-TNF therapy between January 1999 and July 2006. Data from patients using TNF ... Science Daily (press release) Cephalon Spies New Anti-TNF Use in BDC Takeover: Sciatica - Oct 26, 2009 Cephalon Inc.'s potential buyout of BioAssets Development Corp. for $30 million up front, plus an undisclosed payment later if the option is exercised, ... Therapeutics Daily (press release) (registration) ACR: No Increase in Infections with Anti-TNF Therapy - Oct 22, 2009 Explain to interested patients that anti-TNF therapies may carry a risk of infection with joints, ... MedPage Today ACG: Study Marks 10-Year History of Anti-TNF Therapy for Crohn's - Oct 30, 2009 The findings came from Mayo's initial clinical experience with anti-TNF therapy for Crohn's disease. The retrospective cohort study included 492 patients, ... MedPage Today Cephalon Q3 2009 Earnings Call Transcript - Oct 27, 2009 We now have an exciting new opportunity for AMRIX anti-TNF compound. We plan to combine the anti-TNF domain antibody with this technology to develope a new ... Seeking Alpha (blog) ACR: Rheumatoid Arthritis Biologics Increase Risk of Skin Cancer - Oct 18, 2009 Hyrich said the increase represented a strong trend for anti-TNF drugs versus traditional DMARDS, but fell short of statistical significance. ... MedPage Today Yeastward Ho! Alder's Antibody Method Nets Jumbo BMS Deal - Nov 11, 2009 ...with 60 percent pointing to the drug's efficacy, proven comparable to anti-TNF blockbusters Enbrel (etanercept), from Thousand Oaks, Calif. ... Therapeutics Daily (press release) (registration) New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis - Oct 19, 2009 ..."New data demonstrate sustained efficacy of golimumab dosed every four weeks in patients with RA who were previously treated with anti-TNF agents," said Dr. ... Reuters New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and ... - Oct 26, 2009 About CIMZIA® (certolizumab pegol) CIMZIA is the only PEGylated anti-TNF (Tumor Necrosis Factor). CIMZIA( )has a high affinity for human TNF-alpha, ... Reuters Centocor Says Long-Term Data Shows Improvements In Simponi-treated Rheumatoid ... - Oct 19, 2009 Simponi-treated patients who had discontinued previous anti-TNF treatment for any reason sustained improvements in physical function. ... RTT News TB risk varies between anti-TNFs - Nov 1, 2009 It identified 40 reported cases of tuberculosis (TB), all of which were in the anti-TNF cohort. After adjustment, the incidence rate ratio compared to ... Rheumatology Update MorphoSys Receives Regulatory Approval to Start Phase 1b/2a Clinical Trial for ... - Nov 8, 2009 Patients with active RA despite previous therapy with NSAIDs, corticosteroids, DMARDs and/or anti-TNF-alpha will each receive four infusions of either the ... CNNMoney.com (press release) Long-Term Tocilizumab Therapy Results in Increased Response Rates in Patients ... - Oct 19, 2009 Health Assessment Questionnaire Disability Index scores of 0 were seen in 15% of patients in the DMARD-IR group, 8% of those in the anti-TNF-IR group, ... DG News Tocilizumab Shows Sustained Efficacy In Rheumatoid Arthritis - Oct 23, 2009 In anti-TNF-IR and monotherapy patients, the percentages achieving these endpoints increased or were maintained with continued tocilizumab treatment. ... Medical News Today REG-Elan Corporation PLC Subset Data from Two Randomized Phase 3 Trials Show ... - Oct 28, 2009 In patients who had received prior anti-TNF therapy, a more difficult-to-treat patient population, the benefit of TYSABRI was higher. ... Reuters New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With ... - Oct 19, 2009 Psoriatic Arthritis In the Golimumab - A Randomized Evaluation of Safety and Efficacy in Subjects with Psoriatic Arthritis Using a Human Anti-TNF Monoclonal ... Reuters Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation - Oct 26, 2009 ...anticipated scientific progress on its research programs, development of potential pharmaceutical products such as an anti-TNF reactor agent, ... Reuters New data from CIMZIA WELCOME trial to be presented at the ACG meeting - Oct 28, 2009 These exploratory data from the WELCOME trial, which studied patients who had been on the anti-TNF therapy infliximab, but failed or developed a ... News-Medical.net ACR: No Special Benefit Seen with Biologic RA Drugs - Oct 20, 2009 It is compelling in the study that we can do as well with the three drugs combination as with an anti-TNF and methotrexate combination. ... MedPage Today Abbott Submits Marketing Authorization Application of Humira® (adalimumab), a ... - Oct 29, 2009 ...mL for subcutaneous injection (generic name: adalimumab), a fully human monoclonal anti-TNF- antibody jointly developed by the two companies in Japan. ... PharmiWeb.com (press release) Clinic Roundup - Nov 9, 2009 ...corticosteroids, DMARDs and/or anti-TNF-alpha agents, who will receive four infusions of either MOR103 or placebo in three ascending-dose cohorts. ... Therapeutics Daily (press release) (registration) Centocor reports positive data from two Phase III arthritis trials - Oct 21, 2009 ...a once-monthly anti-TNF therapy, sustained clinical response through one year." Republication or redistribution, including by framing or similar means, ... Trading Markets (press release) Newer info on Enbrel, not really that surprising. - Oct 18, 2009 ...safety data that Enbrel presented recently may increase new prescriptions for Enbrel, in particular when comparing against the newer anti-TNF entrants. Gerson Lehrman Group New Options for Treatment of RA and Lupus are Focus of Rheumatology Thought ... - Nov 7, 2009 How will anti-TNF newcomers fit into the rheumatologist's armamentarium? -- Role of other mechanisms, including CTLA4, IL-6, IL-17, JAK, Syk, TNF/PDE4, BTK, ... PR-CANADA.net (press release) Long-Term Registry Study Confirms Safety of Adalimumab for Patients With ... - Oct 26, 2009 ..."These are the first reported findings from this 5-year observational study, and our most important finding is that for this anti-TNF [tumour necrosis ... DG News Infliximab Bests DMARDs in Controlling Radiological Progression in Patients ... - Oct 21, 2009 ..."After initial failure of methotrexate in early RA, addition of anti-TNF is clinically superior to the addition of conventional DMARD therapy, ... DG News Ablynx reports latest technology advances in R&D Update - Oct 19, 2009 Wyeth Pharmaceuticals, also initiated a Phase II study with an anti-TNF-alpha Nanobody to combat inflammatory diseases such as rheumatoid arthritis. ... Trading Markets (press release) Deals of the Week: Trick or Treat! - Oct 30, 2009 That study should help Cephalon gauge the potential for its own anti-TNF (CEP-37247) in sciatic pain, Cephalon Chief Financial Officer and Executive VP ... The IN VIVO Blog (blog) UK cost agency doesn't favour UCB arthritis drug - Oct 20, 2009 It recommends limited use of three other anti-TNF drugs, which work in a similar way to Cimzia by blocking an inflammatory protein. ... Reuters India CBio Limited - Oct 22, 2009 So called anti-TNF drugs have really been a revolution for patients who take them and respond to them - you see not only alleviation of the symptoms, ... Finance News Network UPDATE 1-UCB sees new drug promise, repeats 2009 outlook - Oct 22, 2009 New drug Cimzia had secured a 20.2 percent and 2.9 percent share of new prescriptions in the anti-TNF market to treat respectively bowel disorder Crohn's ... Reuters New Options for Treatment of RA and Lupus are Focus of Rheumatology Thought ... - Nov 6, 2009 How will anti-TNF newcomers fit into the rheumatologist's armamentarium? -- Role of other mechanisms, including CTLA4, IL-6, IL-17, JAK, Syk, TNF/PDE4, BTK, ... PharmaLive.com (press release) ABLYNX PROVIDES AN R&D UPDATE AND ANNOUNCES RECENT TECHNOLOGY ADVANCES - Oct 23, 2009 Also in September, Ablynx's partner Wyeth Pharmaceuticals initiated a Phase II study with an anti-TNF-alpha Nanobody® to combat inflammatory diseases such ... PR-USA.net (press release) New data from efficacy study of CIMZIA in Crohn's disease patients presented - Oct 27, 2009 ...with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years. ... News-Medical.net Elan reports encouraging subset data from Phase III Crohn's disease trials - Oct 28, 2009 ...support that Tysabri is an important treatment option for patients with this chronic and debilitating disease who have failed anti-TNF alpha therapies. ... Trading Markets (press release) New data show long-term benefits of RoActemra (tocilizumab) in rheumatoid ... - Oct 20, 2009 Following failure on two DMARDs, patients have the opportunity to benefit from biologic treatments such as RoActemra and anti-TNF's. ... PharmiWeb.com (press release) STOP RHUMATISMES : LA POLYARTHRITE RHUMATOÃ?DE sort de l'ombre…Enfin - Nov 13, 2009 ...le développement de médications spécifiques, les anti-TNF, auxquels on doit les rémissions de plus en plus nombreuses constatées par les rhumatologues. ... santé log Waarom behandeling niet aanslaat bij sommige reumapatiënten - Nov 13, 2009 Patiënten met reumatoïde artritis (RA) die niet reageren op anti-TNF-behandeling hebben hoge concentraties van IL-7 (interleukine 7). ... Medical facts CIMZIA : AMM européenne pour ce nouvel anti-TNF alfa - Oct 30, 2009 La Commission européenne a délivré une AMM (autorisation de mise sur le marché) européenne à CIMZIA 200 mg solution injectable en seringue préremplie. ... Le Généraliste (Abonnement) Reumatoïde polyartritis: nieuwe diagnoses, nieuwe therapieën! - Nov 11, 2009 De geneesmiddelen die we dan inzetten (anti-TNF-medicatie) gaan dan de aanwezigheid van deze stof in de gewrichten verminderen." Mogen we deze biologische ... Plusmagazine.be Artrite reumatoide: obiettivo remissione - Oct 26, 2009 ...avendo caratteristiche diverse da tutti gli altri biologici, potrà funzionare anche nei malati che non rispondono agli anti-TNF». ... Corriere della Sera T. Heirweg (Fortis BNNP): “Welke omzet gaan nieuwe medicijnen UCB realiseren?â€? - Oct 23, 2009 In de Verenigde Staten wordt Cimzia op de onderhuidse anti-TNF markt in respectievelijk 20,20% en 2,90% voorgeschreven voor de behandeling van de ziekte van ... Cash.be MorphoSys erhält Zulassung für Start von klinischer Phase 1b/2a-Studie für ... - Nov 9, 2009 Corticosteroiden, Antirheumatika der DMARD-Klasse und/oder anti-TNF-alpha-Wirkstoffen unter aktiver rheumatoider Arthritis leiden. ... WELT ONLINE Inflamación intestinal puede provocar la muerte - Oct 27, 2009 ...y que incluso se agrava con el tiempo", explicó el también colaborador del Primer Consenso Mexicano para el uso de agentes anti TNF alfa en la EII. ... TabascoHoy.com Wyeth e Amgen processadas devido à patente do Enbrel® - Oct 29, 2009 A Centocor, divisão da Johnson & Johnson, e os Laboratórios Abbott são outras empresas que utilizam os receptores anti-TNF-alfa, e ambas as companhias ... RCM Pharma Fármaco pode reduzir para metade cirurgias em doentes com colite ulcerosa - Nov 4, 2009 Posteriormente, o Remicade® tornou-se também na primeira terapêutica anti-TNF-alfa aprovada na Europa para o tratamento da colite ulcerosa, a outra doença ... RCM Pharma INFLUENZA A: DERMATOLOGI, VACCINARE MALATI DI PSORIASI - Nov 5, 2009 ...e quella anti-influenzale sono sicure ed efficaci nei pazienti trattati con alcuni farmaci immunosoppressori, inclusi i biologici anti -TNF". ... La Repubblica Artrite reumatoide, via libera al vaccino antinfluenzale - Oct 28, 2009 ...anche se è in cura con biologici anti-TNF», dice Roberta La Rosa dell'Unità di Medicina 1 dell'Ospedale Sant'Andrea di Roma, che assieme a colleghi ... Corriere della Sera SOS POLYARTHRITE RHUMATOÃ?DE : STOP aux RHUMATISMES - Nov 2, 2009 Ce résultat, dû notamment aux traitements modernes (les biothérapies tels les anti-TNF alpha), s'observe également à la radiographie : absence d'anomalies ... santé log Rapport intermédiaire - Premiers résultats prometteurs pour les nouveaux ... - Oct 21, 2009 ...sont prometteuses, avec des pourcentages respectifs de 20,2%[1] et de 2,9%[2] des nouvelles prescriptions (NRx) sur le marché des anti-TNF sous-cutanés. ... Euronext (persbericht) |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |